Opinion|Videos|March 4, 2025
Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer
Panelists discuss how to choose among therapeutic options when multiple molecular alterations are detected, identify patient populations better suited to specific therapies, and share their excitement about potential advances in the HR+/HER2– breast cancer space.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Bardia to All Panelists: How do you choose amongst the therapeutic options if multiple molecular alterations are detected?
- Are there particular patient populations that are better suited to one therapy or class over aanother?
- Dr. Bardia to All Panelists: What other potential advances are you excited about in the HR+/HER2–- breast cancerBC space?
Advertisement
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5